3 research outputs found
E-learning en Atención Primaria: Proyecto de formación en prevención secundaria de cardiopatÃa isquémica en el medio rural
La cardiopatÃa isquémica constituye la primera prioridad en las guÃas de prevención cardiovascular de todo el mundo, siendo considerados los pacientes con más riesgo de presentar un nuevo evento. La calidad de la atención prestada en este colectivo es mejorable. Existen problemas en la accesibilidad a la formación y formación continuada reglada entre los profesionales de la atención primaria de salud en el medio rural. Una intervención múltiple basada en la estructura de los cÃrculos de calidad, apoyada en las Nuevas TecnologÃas de la Información y Comunicación (NTICS), deberÃa mejorar la calidad de la atención recibida por los pacientes del medio rural y reducir el número de ingresos hospitalarios por motivo cardiovascular en mayor grado que el cuidado usual
Clinical effectiveness and bacteriological eradication of three different Short-COurse antibiotic regimens and single-dose fosfomycin for uncomplicated lower Urinary Tract infections in adult women (SCOUT study): study protocol for a randomised clinical trial
Introduction: Uncomplicated lower urinary tract infections (uLUTI) are a common problem in primary care. Current local guidelines recommend the use of a single 3 g dose of fosfomycin. However, most general practitioners (GP) prefer short-course therapies to single-dose therapy. No study has compared head-to-head short-course antimicrobial agents for uLUTIs. Therefore, the aim of this randomised clinical trial is to compare three different short-course antibiotic therapies with a single-dose of fosfomycin for these infections. Methods and analysis: This will be a pragmatic, multicentre, parallel group, open trial. Women aged 18 or older and with symptoms of uLUTI and a positive urine dipstick analysis will be randomised to one of the following four groups: a single dose of 3 g of fosfomycin, 2 days of 3 g of fosfomycin o.d., 3 days of pivmecillinam 400 mg three times per day (t.i.d) or 5 days of nitrofurantoin 100 mg t.i.d. A total sample of 1120 patients was calculated. The primary endpoint is clinical effectiveness at day 7, defined as cure of symptoms reported by the patients in a diary including four symptoms: dysuria, urgency, frequency and suprapubic pain, which will be scored on a 4-point severity scale (not present/mild/moderate/severe). Follow-up visits are scheduled at days 7 (phone call), 14 and 28 for assessing evolution. Urine samples will be collected in the three on-site visits and urine cultures performed. If positive, antibiograms for the three antibiotics studied will be performed. Bacterial eradication will be measured at days 14 and 28